Tirzepatide vs Cagrilintide: What the Research Compares

Tirzepatide and cagrilintide are frequently mentioned in the same conversations about obesity and metabolic pharmacotherapy, but they sit in different drug classes, at different stages of regulatory development, and have been studied in different kinds of trials. This page summarises what the published literature reported about each, and states plainly where direct comparison evidence does not exist.

This page is for educational purposes only and is not medical advice; consult a licensed physician or prescribing clinician about any question concerning diagnosis, treatment, eligibility or medication use. Nothing here describes how any medicine should be used.

The short answer: no head-to-head trial exists

There is no published randomised trial that assigned participants to tirzepatide versus cagrilintide and compared outcomes directly. Reviews that mapped the obesity and type 2 diabetes pipeline described tirzepatide as an approved dual incretin agonist and cagrilintide as an amylin analogue in development, chiefly evaluated in combination with semaglutide rather than against tirzepatide (PMID 41054801). A 2025 review of phase 2 and phase 3 obesity pipelines likewise grouped cagrilintide among investigational agents being advanced in combination approaches, separate from the approved incretin-based products (PMID 40022548).

Because of this, any comparison between the two is an indirect comparison of separate evidence bases, with different trial populations, comparators and endpoints. Network meta-analyses can place drugs on a common scale when they share comparators, but reviewers have repeatedly noted that agents at different development stages carry very different quantities and maturity of evidence (PMID 42419792).

Class and mechanism side by side

How tirzepatide was described mechanistically

Reviews of multifunctional incretin peptides described tirzepatide as a single molecule engineered to activate both the GIP receptor and the GLP-1 receptor, a design intended to combine incretin signalling pathways that influence insulin secretion, gastric emptying and appetite regulation (PMID 40081498). A review of incretin-based therapies for obesity-related diseases placed dual agonism within a broader shift from single-receptor to multi-receptor peptide pharmacology (PMID 40604322).

How cagrilintide was described mechanistically

A review of approved and emerging hormone-based anti-obesity medications described cagrilintide as a long-acting amylin analogue, a class that signals through amylin and calcitonin receptors and has been studied for effects on satiety and food intake — a pathway distinct from incretin receptor agonism (PMID 39676791). Pipeline reviews noted that much of cagrilintide's development has proceeded as a co-formulation with the GLP-1 receptor agonist semaglutide, meaning that the combination rather than cagrilintide alone has been the main unit of study in later-phase work (PMID 41054801).

Regulatory status: the clearest difference

The most concrete difference between the two is regulatory. Reviews of weight management treatment listed tirzepatide among the pharmacological options available to clinicians for obesity management alongside GLP-1 receptor agonists (PMID 40865172). By contrast, reviews of the obesity drug pipeline consistently placed cagrilintide among agents still moving through clinical development rather than among approved products (PMID 40022548).

That distinction matters for how the evidence should be read. Approved medicines have completed large phase 3 programmes with regulator-reviewed labelling; investigational agents may have promising earlier-phase data but have not completed the same evidentiary pathway. Questions about whether any of these medicines are appropriate, available or lawful for a given person belong with a licensed prescribing clinician, not with a summary of literature.

What published studies measured for tirzepatide

A 2024 systematic review and network meta-analysis in The BMJ compared GLP-1 receptor agonists and related agents for type 2 diabetes across glycaemic control, body weight and lipid profile endpoints, and included tirzepatide among the compared treatments (PMID 38286487). That review's framework — pooling randomised trials that shared comparators — is the standard way indirect comparisons between metabolic drugs have been constructed.

A 2026 systematic review and network meta-analysis of drugs for adults with overweight or obesity assessed comparative effects across the available agents, again using randomised trial evidence as its input (PMID 42419792). Reviews of novel GLP-1-based medications described tirzepatide within the group of agents that produced greater average weight reduction in trials than earlier single-agonist therapies, while emphasising that effects varied across populations and trial designs (PMID 41054801).

Beyond weight and glucose, a 2026 review in The Lancet Diabetes & Endocrinology surveyed multisystem outcomes reported for obesity medications, including cardiovascular, hepatic and renal endpoints studied alongside weight change (PMID 42208956). A review of diabetes and chronic kidney disease discussed incretin-based therapies in the context of kidney outcomes in people with type 2 diabetes (PMID 41375628). Mechanistic work has also examined downstream tissue effects: an in vitro study reported mitochondrial adaptations in skeletal muscle following incretin-based therapy exposure (PMID 41852165).

What published studies measured for cagrilintide

The published cagrilintide literature available in these reviews is narrower and earlier-stage. Reviews of emerging hormone-based anti-obesity medications described amylin analogues, including cagrilintide, as an area of active investigation targeting satiety signalling as a complement to incretin pathways (PMID 39676791). Pipeline analyses of phase 2 and phase 3 obesity programmes catalogued cagrilintide-containing regimens among the candidates under evaluation (PMID 40022548).

Reviews of novel GLP-1-based medications noted that combination strategies pairing an amylin analogue with a GLP-1 receptor agonist have been pursued on the rationale that the two mechanisms act on partly separate appetite-regulating circuits (PMID 41054801). Because cagrilintide has largely been studied within such combinations, isolating its independent contribution from published combination data is not straightforward.

Why the comparison is harder than it looks

• Different endpoints. Tirzepatide trials have reported both glycaemic and weight endpoints in people with type 2 diabetes and in people with obesity (PMID 38286487), while cagrilintide has been evaluated primarily for weight-related endpoints in obesity programmes (PMID 40022548).
• Different trial maturity. Reviews classified tirzepatide among approved therapies and cagrilintide among pipeline agents, so the volume of long-term outcome data differs substantially (PMID 40865172).
• Monotherapy versus combination. Much cagrilintide evidence comes from combination regimens, which complicates attribution of effect to the amylin analogue alone (PMID 41054801).
• Indirect comparison limits. Network meta-analyses depend on shared comparators and comparable populations; reviewers using these methods described the resulting estimates as comparative but not equivalent to head-to-head randomisation (PMID 42419792).

Tolerability: What Studies Report

Reviews of incretin-based therapies reported that gastrointestinal effects — including nausea, vomiting and diarrhoea — were the most commonly described adverse events across this drug class, and were a frequent reason for treatment discontinuation in trials (PMID 40604322). A pharmacology handbook chapter on drugs for treating obesity similarly catalogued gastrointestinal intolerance among the recurring safety considerations for appetite-acting agents (PMID 34783910).

Reviews of amylin-analogue development also described gastrointestinal effects as the predominant tolerability signal reported in that class (PMID 39676791). Researchers examining multisystem outcomes of obesity medications noted that safety profiles continue to be characterised as longer follow-up accumulates (PMID 42208956). Because adverse-event reporting depends on trial duration, population and dose-escalation design, tolerability figures from separate programmes are not directly interchangeable. Any individual's risk assessment is a clinical matter for a prescribing physician.

How to read this comparison

Neither this page nor the cited literature identifies a superior agent. The two compounds have not been randomised against each other, their development stages differ, and their mechanisms address overlapping but distinct physiology. Reviews that surveyed the field described a trajectory toward multi-mechanism therapies — dual and triple incretin agonists, and incretin-plus-amylin combinations — rather than a single best molecule (PMID 41054801, PMID 40081498).

For background on each agent individually, see the learn pages on tirzepatide and cagrilintide. Questions about suitability, availability, interactions, monitoring or treatment choice are outside the scope of an educational summary and should be directed to a licensed prescribing clinician.

References

• Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (BMJ, 2024)
• Weight management treatment in obesity (Medicina Clinica, 2025)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Beyond weight loss: multisystem benefits of obesity medications (The Lancet Diabetes & Endocrinology, 2026)
• The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines (Expert Opinion on Investigational Drugs, 2025)
• Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis (BMJ, 2026)
• Incretin-based therapies for the treatment of obesity-related diseases (npj Metabolic Health and Disease, 2024)
• Drugs for Treating Obesity (Handbook of Experimental Pharmacology, 2022)
• Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed (Journal of Clinical Medicine, 2025)
• Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities (Peptides, 2025)
• Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article (Indian Journal of Endocrinology and Metabolism, 2024)
• Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro (Journal of Cachexia, Sarcopenia and Muscle, 2026)